PRIMUS 002
Research type
Research Study
Full title
PRIMUS 002: An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal Carcinoma (PDAC), focusing on biomarker and liquid biopsy development
IRAS ID
221386
Contact name
Judith Dixon-Hughes
Contact email
Sponsor organisation
NHS Greater Glasgow & Clyde
Eudract number
2016-004156-29
ISRCTN Number
ISRCTN34129115
Duration of Study in the UK
5 years, 10 months, 1 days
Research summary
Pancreatic cancer has one of the worst outlooks of any common cancer. Even in the relatively unusual situation of it being potentially operable the chance of cure is very small. There are two main reasons for this. Firstly pancreatic cancer spreads to other parts of the body frequently, secondly even when the cancer is removed there is a fairly high chance of microscopic regions of cancer being left behind
There is a lot of interest in giving treatment (chemotherapy and chemo-radiotherapy) before an operation to try to improve the chances of no cancer being left behind. At present we don’t know which patients are more likely to respond to these types of treatments.This study will examine detailed biopsy results from tissue samples in an attempt to identify which patients are more likely to respond to pre-operative treatment and also to help identify future treatment options.
REC name
Scotland B REC
REC reference
18/SS/0076
Date of REC Opinion
13 Aug 2018
REC opinion
Further Information Favourable Opinion